Marc Martinez-Llordella
Vice President, Biology Quell Therapeutics
Marc serves as Vice President Biology and has forged a deep academic research career focused on Tregs biology and immunological tolerance. His most recent research as Senior Lecturer at King’s College London has combined pre-clinical models and deep phenotyping of clinical samples to identify new strategies to modulate Treg homeostasis and function. From a clinical aspect, Marc has led the immunomonitoring analysis of several trials associated on liver transplantation tolerance. Prior to that he worked in Professor Jeff Bluestones lab at University College San Francisco where he carried out post-doctoral research on the transcriptional profile of CD28 signalling in T cell activation and the analysis of Treg phenotypic plasticity in autoimmunity.
Seminars
- Defining effective Treg modulation to develop a standardized measurement of efficacy beyond the number of Tregs
- Evaluating genomic screening, cytokine measurement, Treg biology and tissue samples to identify the most effective strategy to measure Treg efficacy
- Highlighting the endpoint and efficacy criteria required for regulatory approval
- Discussing the translatability of preclinical mouse model biomarkers to patients
- Discover how Quell’s therapy controls immune responses to protect donor liver function
- Gain translational insights from liver biopsy data demonstrating therapeutic impact
- Understand how additional immune responses can be integrated to enhance transplant success
- Exploring allogenic therapies and rheumatoid treatments in the future of Quell Therapeutics
